Search Results - "MASSIDDA, B"

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients by Ruzzo, A, Graziano, F, Galli, Fabio, Galli, Francesca, Rulli, E, Lonardi, S, Ronzoni, M, Massidda, B, Zagonel, V, Pella, N, Mucciarini, C, Labianca, R, Ionta, M T, Bagaloni, I, Veltri, E, Sozzi, P, Barni, S, Ricci, V, Foltran, L, Nicolini, M, Biondi, E, Bramati, A, Turci, D, Lazzarelli, S, Verusio, C, Bergamo, F, Sobrero, A, Frontini, L, Menghi, M, Magnani, M

“…Background: Dihydropyrimidine dehydrogenase (DPD) catabolises ∼85% of the administered dose of fluoropyrimidines. Functional DPYD gene variants cause…”
Get full text

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial by Cognetti, F., Ruggeri, E.M., Felici, A., Gallucci, M., Muto, G., Pollera, C.F., Massidda, B., Rubagotti, A., Giannarelli, D., Boccardo, F., Cantiani, R., Aglietta, M., Bertetto, O., Cetto, G.L., Orlandini, P., Ferrazzi, E., Nardi, M., della Sofferenza, Sollievo, Manzione, L., Adamo, V., Porcile, G., Lentini, M., Breda, E., Gamucci, T., Tummarello, D., Dogliotti, L., Tumolo, S., Motta, M., Lo Russo, V., De Grande, G., Sacco, C., Gaion, F., Lavarello, A., Nuzzo, A., Clerico, M., Aragona, C., Gernone, A., Morelli, F., Olivito, V., Cupini, Mattioli, R., Marra, A., Antimi, M., Silingardi, V., Labianca, R., Martoni, A., Bortolussi, V., Luoni, M., Rosabian, A., Di Vito, F., Catalano, G., Gebbia, N.

“…The purpose of the study was to evaluate the benefit of adjuvant chemotherapy (AC) versus surgery alone in patients with muscle-invasive bladder cancer (MIBC)…”
Get full text

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial by Lonardi, S, Sobrero, A, Rosati, G, Di Bartolomeo, M, Ronzoni, M, Aprile, G, Massida, B, Scartozzi, M, Banzi, M, Zampino, M G, Pasini, F, Marchetti, P, Cantore, M, Zaniboni, A, Rimassa, L, Ciuffreda, L, Ferrari, D, Barni, S, Zagonel, V, Maiello, E, Rulli, E, Labianca, R

“…Six months of oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk…”
Get full text

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial by Boccardo, F., Rubagotti, A., Guglielmini, P., Fini, A., Paladini, G., Mesiti, M., Rinaldini, M., Scali, S., Porpiglia, M., Benedetto, C., Restuccia, N., Buzzi, F., Franchi, R., Massidda, B., Distante, V., Amadori, D., Sismondi, P.

“…Tamoxifen, for many years the ‘gold standard’ in the adjuvant setting for the management of endocrine sensitive early breast cancer, is associated with an…”
Get full text

Cholesterol esters as growth regulators of lymphocytic leukaemia cells by Mulas, M. F., Abete, C., Pulisci, D., Pani, A., Massidda, B., Dessì, S., Mandas, A.

“…Objective:  Alterations in plasma lipid profile and in intracellular cholesterol homoeostasis have been described in various malignancies; however,…”
Get full text

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study by Roila, F., Ruggeri, B., Ballatori, E., Fatigoni, S., Caserta, C., Licitra, L., Mirabile, A., Ionta, M.T., Massidda, B., Cavanna, L., Palladino, M.A., Tocci, A., Fava, S., Colantonio, I., Angelelli, L., Ciuffreda, L., Fasola, G., Zerilli, F.

“…A combination of aprepitant, a 5-HT3 receptor antagonist (r.a.), and dexamethasone is recommended for the prophylaxis of cisplatin-induced nausea and vomiting…”
Get full text

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial by Boccardo, F, Guglielmini, P, Bordonaro, R, Fini, A, Massidda, B, Porpiglia, M, Roagna, R, Serra, P, Orzalesi, L, Ucci, G, Rubagotti, A

“…Abstract The Italian Tamoxifen Anastrozole (ITA) trial investigated the efficacy of switching to anastrozole for women who were already on adjuvant tamoxifen…”
Get full text

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC) by DI COSTANZO, F, CARLINI, P, GASPERONI, S, DONI, L, MASSIDDA, B, MATTIOLI, R, LOP, A, BARLETTA, E, MOSCETTI, L, RECCHIA, F, TRALONGO, P

“…This study was performed to determine the activity of adding continuous infusion (CI) of 5-fluorouracil (5-FU) to gemcitabine (GEM) vs GEM alone in advanced…”
Get full text

Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer by Piras, F, Ionta, M T, Lai, S, Perra, M T, Atzori, F, Minerba, L, Pusceddu, V, Maxia, C, Murtas, D, Demurtas, P, Massidda, B, Sirigu, P

“…Nestin, an intermediate filament protein, has traditionally been noted for its importance as a neural stem cell marker. However, in recent years, expression of…”
Get full text

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study by Vici, P., Brandi, M., Giotta, F., Foggi, P., Schittulli, F., Di Lauro, L., Gebbia, N., Massidda, B., Filippelli, G., Giannarelli, D., Di Benedetto, A., Mottolese, M., Colucci, G., Lopez, M.

“…The Gruppo Oncologico Italia Meridionale 9902 trial compared four cycles of high-dose epirubicin plus cyclophosphamide (EC) with four cycles of docetaxel…”
Get full text

Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101) by Comella, P., Filippelli, G., De Cataldis, G., Massidda, B., Frasci, G., Maiorino, L., Putzu, C., Mancarella, S., Palmeri, S., Cioffi, R., Roselli, M., Buzzi, F., Milia, V., Gambardella, A., Natale, D., Bianco, M., Ghiani, M., Masullo, P.

“…Background: Triplet regimens were occasionally reported to produce a higher response rate (RR) than doublets in locally advanced or metastatic non-small-cell…”
Get full text

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients by COMELLA, P, FRASCI, G, CIOFFI, R, CARNICELLI, P, MASSIDDA, B, BUZZI, F, FILIPPELLI, G, MAIORINO, L, GUIDA, M, PANZA, N, MANCARELLA, S

“…The aim of this study was to assess whether a combination of gemcitabine (GEM) with either paclitaxel (PTX) or vinorelbine (VNR) could be more effective than…”
Get full text

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial by Comella, P., Massidda, B., Filippelli, G., Palmeri, S., Natale, D., Farris, A., De Vita, F., Buzzi, F., Tafuto, S., Maiorino, L., Mancarella, S., Leo, S., Lorusso, V., De Lucia, L., Roselli, M.

“…Purpose:: The primary end point of this phase III trial was to compare the response rate (RR) of oxaliplatin (OXA) plus levo-folinic acid (l-FA) and…”
Get full text

Progress in the treatment of gastrointestinal cancer by Massidda, B., Rougier, P.

Get full text

5-Year Results of Cisplatin-Epirubicin-Vinorelbine (PEV) Combination as Primary Chemotherapy in T2-3, N0-2 Breast Cancer Patients: A Multicentre Phase II Study by Barni, S, Visini, M, Piazza, E, Ionta, M T, Ardizzoia, A, Arnoldi, E, Fava, S, Pinotti, G, Torretta, F, Corradini, G, Villa, S, Nosenzo, A M, Massidda, B, Cazzaniga, M E

“…The aim this study was to assess the efficacy of cisplatin-epirubicin-vinorelbine, as primary chemotherapy, in reducing the tumour burden in T 2-3 N 0-2 breast…”
Get full text

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients : a Southern Italy Cooperative Oncology Group phase II study by COMELLA, P, MASSIDDA, B, PALMERI, S, FARRIS, A, DE LUCIA, L, NATALE, D, MAIORINO, L, TAFUTO, S, DE CATALDIS, G, CASARETTI, R

“…Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL…”
Get full text

A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer by Tomao, S, Romiti, A, Massidda, B, Ionta, M T, Farris, A, Zullo, A, Brescia, A, Santuari, L, Frati, L

“…Advanced pancreatic cancer (APC) constitutes a poor-prognosis disease with few and disappointing therapeutic options. In recent years chemotherapy has…”
Get more information

Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study by Palmeri, S, Vaglica, M, Spada, S, Filippelli, G, Farris, A, Palmeri, L, Massidda, B, Misino, A, Ferraù, F, Comella, G, Leonardi, V, Condemi, G, Mangiameli, A, De Cataldis, G, Macaluso, M C, Cajozzo, M, Iannitto, E, Danova, M

“…We conducted a multicenter phase II study to evaluate the clinical efficacy, toxicity, and dose intensity of a new weekly schedule of docetaxel and gemcitabine…”
Get more information

1301 The transcription factor p53 enhances the long-term survival effect of survivin in T4 breast cancer patients – 10-year results from a single institution by Atzori, F, Ionta, M.T. Maria Teresa, Maxia, C, Deidda, M.C, Piras, F, Pusceddu, V, Murtas, D, Demurtas, P, Minerba, L, Massidda, B

Get full text

PP92 Molecular changes predicting response to therapy and prognosis among patients with stage IIIB breast cancer by Atzori, F, Palmieri, G, Ionta, M.T, Sini, M.C, Budroni, M, Deidda, M.C, Pusceddu, V, Piras, F, Demurtas, P, Massidda, B

Get full text